AI Engines For more Details: Perplexity Kagi Labs You
Respiratory Tract Infections: Dirithromycin is commonly prescribed for respiratory tract infections such as community-acquired pneumonia, acute exacerbations of chronic bronchitis, and pharyngitis/tonsillitis caused by susceptible bacteria.
Skin and Soft Tissue Infections: It may also be used to treat skin and soft tissue infections caused by susceptible bacteria, including cellulitis and impetigo.
Genitourinary Tract Infections: Dirithromycin can be effective against genitourinary tract infections such as urethritis and cervicitis caused by susceptible bacteria.
Sexually Transmitted Infections: In some cases, dirithromycin may be used to treat sexually transmitted infections like chlamydia and non-gonococcal urethritis, although other antibiotics are more commonly used for these conditions.
Helicobacter pylori Infection: Dirithromycin may be part of combination therapy for eradicating Helicobacter pylori bacteria in patients with peptic ulcer disease or chronic gastritis.
Precautions and Side Effects: Like other antibiotics, dirithromycin can cause side effects such as gastrointestinal disturbances (nausea, vomiting, diarrhea), abdominal pain, and allergic reactions (rash, itching, swelling). It may also interact with other medications, so it's essential to inform your healthcare provider about all medications you are taking.
Not Suitable for All Bacterial Infections: Dirithromycin is effective against certain types of bacteria but may not be suitable for all bacterial infections. It's essential to use dirithromycin only as prescribed by a healthcare professional and to complete the full course of treatment, even if symptoms improve before the medication is finished.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.9 | -0.04 |
| Allergies | 5.7 | 4.3 | 0.33 |
| Allergy to milk products | 2 | 1 | 1 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.9 | 7.7 | -0.12 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.7 | 0.9 | 3.11 |
| Ankylosing spondylitis | 4.1 | 1.8 | 1.28 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 5.9 | 3.4 | 0.74 |
| Atherosclerosis | 2.1 | 2.4 | -0.14 |
| Atrial fibrillation | 4.1 | 2.5 | 0.64 |
| Autism | 10.7 | 10.7 | 0 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 2.4 | 2.4 | |
| Bipolar Disorder | 1.8 | 1.7 | 0.06 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 3.4 | -2.78 |
| Carcinoma | 4.4 | 2.6 | 0.69 |
| Celiac Disease | 3 | 4.3 | -0.43 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 6 | 7.7 | -0.28 |
| Chronic Kidney Disease | 4 | 3.4 | 0.18 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 2 | 0.2 |
| Chronic Urticaria (Hives) | 0.8 | 1.8 | -1.25 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 7.7 | 2.2 | 2.5 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 3 | -0.67 |
| COVID-19 | 10.9 | 14.9 | -0.37 |
| Crohn's Disease | 9.2 | 6.9 | 0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 2 | 1.4 | 0.43 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 12.8 | 11 | 0.16 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2.6 | -0.53 |
| Endometriosis | 2.3 | 2 | 0.15 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.3 | 2.8 | 0.18 |
| erectile dysfunction | 0.8 | 0.3 | 1.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 5.7 | 4.9 | 0.16 |
| gallstone disease (gsd) | 3.1 | 1.6 | 0.94 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 2.7 | 2.5 | 0.08 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.6 | 1 | 1.6 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 3.6 | 2.4 | 0.5 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 1.8 | 2.2 | -0.22 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.2 | 6.8 | -0.31 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 2.9 | 0.3 | 8.67 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 9.1 | 11.5 | -0.26 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 8.8 | 6.4 | 0.38 |
| ischemic stroke | 2.6 | 1.1 | 1.36 |
| Liver Cirrhosis | 8 | 5.3 | 0.51 |
| Long COVID | 8.1 | 9.3 | -0.15 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.9 | 1.6 | -0.78 |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | 0 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 8.3 | 9.6 | -0.16 |
| Mood Disorders | 13.4 | 8.9 | 0.51 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 8.4 | 7 | 0.2 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 1.6 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.3 | 5.9 | -0.11 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 11.6 | 10.6 | 0.09 |
| obsessive-compulsive disorder | 5.2 | 4.8 | 0.08 |
| Osteoarthritis | 2.7 | 1.7 | 0.59 |
| Osteoporosis | 1.9 | 1.9 | 0 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 8.8 | 7.7 | 0.14 |
| Polycystic ovary syndrome | 7.3 | 3.7 | 0.97 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 3.8 | 4 | -0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9 | 4.7 | 0.91 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.8 | 3.6 | 1.17 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 2.6 | 3.2 | -0.23 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.6 | 1.67 |
| Stress / posttraumatic stress disorder | 3.1 | 3.3 | -0.06 |
| Systemic Lupus Erythematosus | 4.3 | 2.4 | 0.79 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 4.5 | 4.4 | 0.02 |
| Type 2 Diabetes | 9.3 | 8.4 | 0.11 |
| Ulcerative colitis | 5.8 | 8.2 | -0.41 |
| Unhealthy Ageing | 6.2 | 2.9 | 1.14 |
| Vitiligo | 2.5 | 2 | 0.25 |
